Nabriva Therapeutics AG Stock News

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q4 2021 Results - Earnings Call Transcript

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in

Nabriva Therapeutics Plc (NBRV) shares closed today at 1.9% above its 52 week low of $0.52, giving the company a market cap of $31M. The stock is currently down 5.8% year-to-date, down 80.3% over the past 12 months, and down 99.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 30.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 736.5% The company's stock price performance over the past 12 months lags the peer average by 837.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nabriva Therapeutics Plc (NBRV) shares closed today 13.5% higher than it did at the end of yesterday. The stock is currently up 13.5% year-to-date, down 71.9% over the past 12 months, and down 99.2% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $0.70 and as low as $0.52 this week.Shares closed 80.5% below its 52-week high and 31.0% above its 52-week low.Trading volume this week was 11.3% lower than the 10-day average and 31.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance over the past 12 months lags the peer average by 895.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nabriva Therapeutics plc (NASDAQ:NBRV) with the stream of -5.56% also noticed, India British American Tobacco p.l.c. (NYSE:BTI) encountered a rapid change of 0.03% in the last hour of Thursdays trading The post Stock Gigantic Turns: Nabriva Therapeutics plc (NASDAQ:NBRV), British American Tobacco p.l.c. (NYSE:BTI) appeared first on Stocks Equity .

Meeting to Reconvene on January 14, 2022 Meeting to Reconvene on January 14, 2022

Citigroup Inc. (NYSE:C) with the stream of 1.89% also noticed, India Nabriva Therapeutics plc (NASDAQ:NBRV) encountered a rapid change of 1.52% in the last hour of Tuesdays trading session. Citigroup The post Beholding Stock: Citigroup Inc. (NYSE:C), Nabriva Therapeutics plc (NASDAQ:NBRV) appeared first on Stocks Equity .

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand beginning on Monday, January 10 at 7:00am ET. Management will also host investor meetings January 10-13, 2022.

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn

Nabriva Therapeutics plc (NASDAQ:NBRV) with the stream of -6.31% also noticed, India CooTek (Cayman) Inc. (NYSE:CTK) encountered a rapid change of -7.04% in the last hour of Tuesdays trading session. The post Golden Stock: Nabriva Therapeutics plc (NASDAQ:NBRV), CooTek (Cayman) Inc. (NYSE:CTK) appeared first on Stocks Equity .

Nabriva Therapeutics plc (NASDAQ:NBRV) with the stream of -3.19% also noticed, India Tellurian Inc. (AMEX:TELL) encountered a rapid change of -1.84% in the last hour of Fridays trading session. Nabriva The post Bright Stock in Review: Nabriva Therapeutics plc (NASDAQ:NBRV), Tellurian Inc. (AMEX:TELL) appeared first on Stocks Equity .

Analysts expect that Nabriva Therapeutics plc (NASDAQ:NBRV) will post $8.79 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Nabriva Therapeutics earnings. The lowest sales estimate is $7.15 million and the highest is $9.85 million. Nabriva Therapeutics reported sales of $2.46 million during the same quarter []

Zacks Investment Research upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 price objective on the biotechnology companys stock. According to Zacks, Nabriva Therapeutics is a biopharmaceutical company engaged in the research []

The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St